Imperial College London

ProfessorLukeHoward

Faculty of MedicineNational Heart & Lung Institute

Professor of Practice (Cardiopulmonary Medicine)
 
 
 
//

Contact

 

+44 (0)20 3313 3171l.howard Website

 
 
//

Location

 

B3113Hammersmith HospitalHammersmith Campus

//

Summary

 

Pulmonary Hypertension Clinical Trials

Early phase studies examining new targets with novel clinical end-points. Current and recent examples include:

  • Chief Investigator of randomised trial of intravenous iron in idiopathic pulmonary arterial hypertension (IPAH)
  • Chief Investigator (UK) for safety and efficacy study of pulmonary artery denervation with high-energy ultrasound
  • Open-label dose ranging trial of dicholoracetate in IPAH
  • Anti-IL-6 in IPAH and connective-tissue PAH
  • Chief Investigator (UK) in Phase II study of Macitentan in chronic thromboembolic PH
  • Intravenous apelin on resting and exercise haemodynamics in PAH

Late phase with novel end-points:

  • Chief Investigator (UK) for activity-based exploratory outcome measures in randomised trial of IP3 agonist in PAH 

Pulmonary Embolism

show research
  • Physiological impact of chronic thromboembolic disease
  • Genetic and molecular profiling of pulmonary embolism

Cardiopulmonary Physiology

show research
  • Physiological phenotyping of pulmonary vascular diseases with exercise, haemodynamics and wave-intensity analysis
  • Using exercise endpoints in clinical trials